Healthcare's share of the global PE and VC deal count will likely continue decreasing in 2024, according to a new Pitchbook report. The report also predicted that generative AI and surgical robotics will continue to be hot areas of interest for investors, and that there will be at least three digital health IPOs next year.
Healthcare M&A deals are expected to pick up over the next few months, and one expert is predicting that the biopharma sector in particular will see especially robust activity. M&A lawyer Matt Gardella said there are three sets of market circumstances that will lead to an influx of biopharma deals: a looming patent cliff, shrinking valuations and a weak IPO market.
A new independent study from Phyx Primary Care’s Innovation Lab points to measurable improvements in physician burnout, documentation efficiency, and key VBC metrics among primary care practices.
As macroeconomic forces continue to negatively impact the healthcare sector, health tech experts predict that 2023 will be another slow year for the IPO market. However, they think consolidation deals will continue to be a constant, according to a new report.
The five life sciences IPOs this week continues the steady march companies are making to the public markets this year. This week's activity follows a first quarter that Renaissance Capital calculates was the busiest for newly public companies since 2000. Healthcare IPOs continued to dominate the stock offerings.
Healthcare technology companies raised a record of $15.3 billion in 2020, according to a report from Silicon Valley Bank. For the first time, digital health companies surpassed biopharma for the number of deals.
One year ago, in collaboration with Lake Whillans and our sister site MedCity News, we launched the inaugural Life Sciences Law Firm Index to recognize law firms that are the most active and relevant for life science companies. Over the course of 2016, we have published updates to the Index, each focusing on a different practice area. Today, […]
Break down the silos. Take control of your provider data.
With private and corporate financing rounds in excess of $400 million, the allure of a biotech IPO has drastically declined in 2016. Will that phenomenon roll into 2017 -- or are the public markets poised to rebound? One investor has some opinions.